8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Farallon Capital Thomas Steyer | 8,239,123 | $204,330,250 | +1% | 1.03% |
2. | ARK Investment Management Catherine D. Wood | 7,068,029 | $175,287,119 | +9% | 1.45% |
3. | Citadel Investment Group Ken Griffin | 2,062,246 | $51,143,701 | +38% | 0% |
4. | Kynam Capital Derrick Tang | 1,756,158 | $43,552,718 | +35% | 2.57% |
5. | Redmile Group Jeremy Green | 1,528,567 | $37,908,462 | -6% | 2.64% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$18.35 | 5,674 | 117,294 | 2025-04-01 | Filing | ||
$18.35 | 30,663 | 986,249 | 2025-04-01 | Filing | ||
$18.35 | 7,434 | 190,216 | 2025-04-01 | Filing | ||
$18.35 | 3,015 | 44,512 | 2025-04-01 | Filing | ||
$17.73 | 20,997 | 65,742 | 2025-04-02 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 697 | $13,612 | 0% | |
2. | 5 | $98 | 0% |